Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 20 versus MODEYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 20 versus MODEYSO.
LARIN 1/20 vs MODEYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
400 mg orally once daily with food
None Documented
None Documented
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive